About Sequent Penems Private Limited
Data last updated:
Sequent Penems Private Limited is a private limited company based in Bangalore, Karnataka, India, a subsidiary of Solara Active Pharma Sciences Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 May 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24233KA2010PTC053548. Its GSTIN is 29AAOCS3943H3ZS (Karnataka). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹4.53 Cr. It is led by directors Salim Sadiq Shaikh and Akash Suresh Puranik.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Bangalore, Karnataka.
As per the financials filed for FY 2025, the company reported a revenue of ₹70.86 Lakh. For the same year it recorded a net loss of ₹28.05 Lakh (net margin -39.6%) and EBITDA of ₹3.87 Lakh (EBITDA margin 5.5%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years.
As per MCA filings, the company has open charges of ₹10 Cr and satisfied charges of ₹90 Cr on record. Court records list 6 cases involving the company, including 3 filed by the company and 3 filed against it; 2 cases are pending. The company has 1 deal on record (1 secondary share transfer); the latest was in February 2021. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Sentonssa Wellness Private Limited with revenue of ₹71.16 Lakh.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sequent.in.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressSymbio House No. 1215 24th Main, 11th Cross Hsr Layout 1st Sector, Bangalore, Karnataka, India – 560102
- IndustryPharma, Drug Formulation & Development, Pharma Contract R&D
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Financials of Sequent Penems Private Limited FY 2025 filings available
Sequent Penems Private Limited reported revenue of ₹70.86 Lakh for FY 2025.
Compounded Annual Growth Rate (CAGR) of Sequent Penems Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 16% over three years. EBITDA rose 102% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Sequent Penems Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹3.87 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹28.05 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Sequent Penems Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -39.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sequent Penems are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Sequent Penems Private Limited
Sequent Penems Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sentonssa Wellness Private Limited | ₹71.16 Lakh (FY 2024) | •••• | •••• | 0.0% | •••• | Siddhpur, Gujarat, India |
| French Biologicals Private Limited | ₹71.09 Lakh (FY 2024) | •••• | •••• | 9.0% | •••• | Hyderabad, Telangana, India |
| Amcor Pharma Private Limited | ₹71.03 Lakh (FY 2025) | •••• | •••• | -11.0% | •••• | Amravati, Maharashtra, India |
| Nevuron India Private Limited | ₹70.92 Lakh (FY 2025) | •••• | •••• | 20.0% | •••• | New Delhi, Delhi, India |
| Kesar Drugs Private Limited | ₹70.91 Lakh (FY 2025) | •••• | •••• | 4984.0% | •••• | Panchkula, Haryana, India |
| Sequent Penems Private Limited this company | ₹70.86 Lakh (FY 2025) | •••• | •••• | •••• | Bangalore, Karnataka, India | |
| Arb Remedies Private Limited | ₹70.84 Lakh (FY 2025) | •••• | •••• | 81.0% | •••• | Pune, Maharashtra, India |
| Vizag Pharmaceuticals Private Limited | ₹70.81 Lakh (FY 2016) | •••• | •••• | -52.0% | •••• | Hyderabad, Telangana, India |
| Banureet Labs Private Limited | ₹70.81 Lakh (FY 2024) | •••• | •••• | 25.0% | •••• | Dehradun, Uttarakhand, India |
| Diagon Vanguard Diagnostics India Private Limited | ₹70.58 Lakh (FY 2025) | •••• | •••• | 276.0% | •••• | New Delhi, Delhi, India |
| PJS Pharma Private Limited | ₹70.55 Lakh (FY 2023) | •••• | •••• | 5595.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Sequent Penems by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Sequent Penems Private Limited
Sequent Penems Private Limited is audited by P.Chandrasekar LLP for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| P.Chandrasekar LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Sequent Penems Private Limited
Sequent Penems has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Salim Sadiq Shaikh Also directs: VPL Chemicals Private Limited, Copernicium Pharmaceuticals Private Limited, Anveta Therapeutics Private Limited and 5 more | Director | 25 Apr 2024 | 2 Years 5 Months | Current |
| Akash Suresh Puranik Also directs: VPL Chemicals Private Limited, Copernicium Pharmaceuticals Private Limited, Symbio Generrics India Private Limited and 1 more | Director | 25 Apr 2024 | 2 Years 5 Months | Current |
Ownership and Shareholding of Sequent Penems Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Sequent Penems Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Sep 2024 | Others | ₹10 Cr | Open |
| 09 Mar 2012 | State Bank of Hyderabad | ₹90 Cr | Satisfied |
Total charge records: 2 View all charges
Deals & Funding of Sequent Penems Private Limited
Sequent Penems Private Limited has 1 deal on record (1 secondary share transfer); the latest was in February 2021.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Feb 2021 | Secondary share transfer | Undisclosed | Buyer: Solara Active Pharma Sciences Limited |
Full deal history
All 1 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Sequent Penems Private Limited
Sequent Penems Private Limited has 6 court cases on record: 3 filed by Sequent Penems, 3 filed against it. 2 cases are pending and 4 are disposed. Status as checked between 21 Sep 2026 and 30 Sep 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 1 | 1 |
| District courts | 2 | 2 | 1 |
Cases on record (5 of 6)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Filed against the company by an individual | Pending |
| District court, BENGALURU RURAL, Karnataka | Court case (Com.O.S.) | Filed against the company by an individual | Pending |
| District court, BENGALURU RURAL, Karnataka | Commercial matter | Filed against the company by an individual | Disposed |
| High Court of Karnataka | Arbitration matter | Filed by the company against an individual | Disposed |
| High Court of Karnataka | Appeal | Filed by the company against an individual | Disposed |
Full case history
All 6 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Sequent Penems Private Limited
Sequent Penems Private Limited has a workforce of 0 employees as of Apr 07, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
News related to Sequent Penems Private Limited
Recent Activity on Sequent Penems Private Limited
Sequent Penems Private Limited has 9 board changes on record since 2010: 2 appointments and 7 cessations. The latest: Akash Suresh Puranik was appointed as Director on 25 Apr 2024.
4 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Sequent Penems Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sequent Penems Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sequent Penems Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sequent Penems Private Limited
Sequent Penems has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAOCS3943H3ZS | Karnataka | Active | 12 Jan 2018 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sequent Penems Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sequent Penems Private Limited
Sequent Penems is an active private limited company based in Bangalore, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 May 2010 (16+ years old) and is registered under CIN U24233KA2010PTC053548.
Sequent Penems reported revenue of ₹70.86 Lakh for FY 2025.
Sequent Penems has 2 current directors:
- Salim Sadiq Shaikh - Director
- Akash Suresh Puranik - Director
Sequent Penems reported a net loss of ₹28.05 Lakh (net margin -39.6%) and EBITDA of ₹3.87 Lakh (EBITDA margin 5.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Sequent Penems is 16% over three years. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Sequent Penems is 29AAOCS3943H3ZS, registered in Karnataka. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Sequent Penems is U24233KA2010PTC053548. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sequent Penems has 6 court cases on record: 3 filed by the company and 3 filed against it. 2 are pending. Most are in the high courts.
Sequent Penems was incorporated on 10 May 2010, making it 16+ years old. It is registered with the Registrar of Companies, Bangalore.
Sequent Penems has 1 deal on record (1 secondary share transfer); the latest was in February 2021.
The peers of Sequent Penems by revenue are Sentonssa Wellness Private Limited, French Biologicals Private Limited, Amcor Pharma Private Limited, Nevuron India Private Limited, Kesar Drugs Private Limited and 5 more, all in the Pharma industry (Formulations).